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Human immunodeficiency virus drug resistance (HIVDR) in cohorts of patients initiating antiretroviral
therapy (ART) at clinics in Chennai and Mumbai, India, was assessed following World Health Organization
(WHO) guidelines. Twelve months after ART initiation, 75% and 64.6% of participants at the Chennai
and Mumbai clinics, respectively, achieved viral load suppression of <1000 copies/mL (HIVDR prevention).
HIVDR at initiation of ART (P <.05) and 12-month CD4 cell counts <200 cells/mL (P <.05) were associated with
HIVDR at 12 months. HIVDR prevention exceeded WHO guidelines (‡70%) at the Chennai clinic but was
below the target in Mumbai due to high rates of loss to follow-up. Findings highlight the need for defaulter
tracing and scale-up of routine viral load testing to identify patients failing first-line ART.
At the end of 2009, 33.3 million people worldwide
were living with human immunodeficiency virus (HIV)
infection [1], including an estimated 2.3 million in
India [2]. Additionally, an estimated 5.2 million people
in low- and middle-income countries were receiving
antiretroviral therapy (ART) for HIV [3].
India began ART scale-up in 2004 [2], and as of
January 2011, approximately 393 632 HIV-infected
adults and children were receiving ART at 293 centers
throughout the country [4]. In the context of ART
scale-up and maintaining large numbers of patients
on ART, emergence of HIV drug resistance (HIVDR)
is inevitable. HIVDR and associated treatment failure
pose major challenges to successful global ART scale-
up and necessitate surveillance of acquired HIVDR
in populations receiving ART as well as identification
of ART program practices that can be optimized to
minimize HIVDR emergence [5]. In India, there are
few reports on ART efficacy or HIVDR [6–11].
The World Health Organization (WHO) developed
a population-level HIVDR assessment and prevention
strategy that includes standardized surveys for assessing
acquired HIVDR and associated program factors at
sentinel ART clinics [12]. The National AIDS Research
Institute, in collaboration with the National AIDS
Control Organization and WHO, implemented a survey
of acquired HIVDR at the ART center at the Government
Hospital of Thoracic Medicine, Tambaram, Chennai,
and at the ART center at J. J. Hospital, Mumbai. Both
clinics have provided ART free of charge since 2004.
The aim of this survey was to pilot the WHO survey
of acquired HIVDR at 2 ART clinics for the purpose
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of identifying patient and program predictors of HIVDR in
order to inform national recommendations on effective
management of HIVDR at these and other ART clinics in
India.
METHODS
A prospective survey of acquired HIVDR was adapted from
WHO generic recommendations and then implemented [12].
Per WHO guidance, an effective sample size of 96 permits es-
timation of clinic-level HIVDR prevention (as defined by viral
load [VL] ,1000 copies/mL) 12 months after initiation of
ART [12]. To achieve the necessary sample size, 150 patients
initiating ART at the Chennai clinic and 148 patients initi-
ating ART at the Mumbai clinic were enrolled. Enrollment
occurred in March–April 2008 in Chennai and November–
December 2007 in Mumbai. Patients were evaluated prior to
ART initiation and after 12 months of ART. Patients who
died or transferred to other ART clinics were excluded from
the endpoint prevalence analysis, and only data from the
first consecutive 96 patients with evaluable endpoints were
analyzed. The ART centers at J. J. Hospital and Government
Hospital of Thoracic Medicine were chosen because they
had been functional for .4 years, maintained the necessary
patient records, and had adequate facilities for specimen
collection, processing, storage, and shipping. This survey
was approved by the ethics committees of both hospitals
and the institutional ethics committee of the National AIDS
Research Institute.
Survey Participants
HIV-infected individuals $18 years initiating first-line ART
on or after the survey start date who agreed to participate
after providing written informed consent were enrolled con-
secutively. Patients with previous exposures to antiretroviral
(ARV) drugs were included, with the exception of patients
who had previously started and stopped first-line ART and in-
dividuals transferring from another ART clinic on a 3-drug
first-line regimen. All enrolled patients initiated standard
first-line ART [13]. Patients received either a combinations
of zidovudine/stavudine, lamivudine, and nevirapine or
efavirenz. Survey participants were assigned unique HIVDR
survey codes. Plasma specimens were collected from all in-
dividuals on the day of ART initiation (baseline) for HIVDR
genotyping. At 12 months, plasma specimens were collected
from all patients still on first-line ART for HIV RNA and
HIVDR testing (if VL $1000 copies/mL). The following sur-
vey endpoints were assessed: on first-line ART at 12 months,
death, stop, transfer out, or loss to follow-up. CD4 testing
was performed at ART initiation and at 6-month intervals.
The following survey endpoints were defined:
1. HIVDR prevention: HIV RNA ,1000 copies/mL
after 12 months of ART. The WHO target for HIVDR
prevention is $70% VL suppression 12 months after ART
initiation [12].
2. Detected HIVDR: HIV RNA $1000 copies/mL at
12 months and $1 HIVDR mutation as defined by the
Stanford HIVDR database [14].
3. Possible HIVDR: patients who stopped ART during the
12 months after initiation, patients lost to follow-up and
patients with HIV RNA $1000 copies/mL at 12 months and
no detected HIVDR.
Laboratory Analysis and Data Collection
Blood specimens were processed for plasma separation at the
ART clinics. Specimens were stored at 220C and transported
to the National AIDS Research Institute, Pune, on dry ice.
HIV VL was analyzed using an Amplicor HIV monitor (MWP
1.5) and/or a COBAS Amplicor HIV monitor kit version 1.5
(COBAS 1.5; Roche Diagnostics, Branchburg, New Jersey).
HIVDR genotyping was performed using ViroSeq version 2.0
(Abbott, Wiesbaden, Germany) and sequencing was performed
using an ABI 3100 Genetic Analyzer according to the manu-
facturer’s instructions. HIVDR was defined as the presence of
1 or more resistance mutations causing low-, intermediate-, or
high-level resistance per the Stanford HIVDR database [14].
Patient demographic and clinical data were abstracted from
medical records, and adherence to ART was estimated at
survey endpoint using a 30-day visual analogue scale (VAS).
Statistical Analysis
The prevalence of HIVDR prevention (VL suppression) at
12 months and prevalence of detected HIVDR was estimated
with 95% binomial exact confidence interval. Association of
patient factors with HIVDR at 12 months was tested using
Pearson v2 test and Fisher exact test. Odds ratios (ORs) and
adjusted ORs in univariate and multivariate analyses were
calculated using a forward logistic regression method. Patient
factors analyzed were age, sex, baseline and endpoint CD4
count, weight at baseline and endpoint, WHO clinical stage
at ART initiation, adherence (VAS), previous ARV exposure,
presence of HIVDR at baseline, ART regimen type, and regimen
substitution. All statistical analyses were performed with SPSS
software version 15.
RESULTS
A total of 150 patients were enrolled at the Chennai clinic and
148 patients were enrolled at the Mumbai clinic. After
12 months at the Chennai clinic, 15 patients had transferred out,
11 died, 19 were lost to follow-up, 1 stopped ART, and 104
were still on first-line ART. At the Mumbai clinic, 11 had
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transferred out, 13 died, 29 were lost to follow-up, and 95 were
still on first-line ART. No patient at either clinic switched to
second-line ART. Patients who transferred out or died were
censored from analyses. Among the remaining patients, the
first consecutive 96 with the following endpoints were ana-
lyzed: (1) on ART at 12 months, (2) lost to follow-up, and (3)
stopped. An overview of survey design and results is found
in Figure 1. Among the first 96 patients analyzed at 12 months,
81 (84.4%) were on first-line ART at the Chennai clinic and
72 (75%) were on first-line ART at the Mumbai clinic. Four-
teen (14.6%) were lost to follow-up at the Chennai clinic and
24 (25%) were lost to follow-up at the Mumbai clinic. Seventy-
two (75%) from Chennai and 62 (64.6%) from Mumbai
achieved VL suppression. Among those on ART at 12 months,
72 of 81 (89%) and 62 of 72 (86%) achieved virologic sup-
pression while 9 (11%) and 10 (14%) patients experienced
virologic failure at the Chennai and Mumbai clinics, re-
spectively. Among those with virological failure, 89% (8 of 9)
had detected HIVDR at the Chennai clinic and 90% (9 of 10)
had detected HIVDR at the Mumbai clinic. Baseline charac-
teristics of the 96 patients analyzed at endpoint and the
baseline/endpoint characteristics of patients with endpoint
VL and/or HIVDR results are shown in Table 1.
Genotypic HIV Resistance Mutations
At baseline, 1 or more resistance mutations were detected in 5 of
96 (5.2%) patients at the Chennai clinic and 10 of 96 (10.4%)
patients at the Mumbai clinic.
Baseline HIVDR at Chennai
At the Chennai clinic, 3 of 5 patients had the nucleoside
reverse transcriptase inhibitor (NRTI) mutation M184V and
2 of 5 had at least 1 thymidine analogue mutation (TAM). One
patient had the protease inhibitor (PI) mutation M46L.
Baseline HIVDR at Mumbai
At the Mumbai clinic, 5 of 10 patients had the NRTI mutation
M184V or M184I and 3 of 10 had at least 1 TAM. Most
patients (9 of 10) had high-level resistance to nevirapine
conferred by K103 N/S, G190A, Y181C/I/V, or Y188H/L/Y.
No PI mutations were detected.
Overall HIVDR Survey Outcomes
Following WHO guidelines, HIVDR prevention was estimated
to have occurred in 72 of 96 patients (75%; 95% confidence
interval [CI], 65.1%–83.3%) at the Chennai clinic and 62 of
96 patients (64.6%; 95% CI, 54.2%–74.1%) at the Mumbai
clinic. Possible HIVDR (VL $1000 copies/mL and no detected
Figure 1. Survey design and results from 2 antiretroviral therapy clinics, Chennai and Mumbai, India. Abbreviations: ART, antiretroviral therapy; HIV,
human immunodeficiency virus; HIVDR, HIV drug resistance; VL, viral load.
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HIVDR 1 lost to follow-up 1 stopped) was 16.6% (16 of
96 patients) at Chennai and 26% (25 of 96 patients) at
Mumbai. Detected HIVDR was present in 8 of 96 patients
(8.3%; 95% CI, 3.7%–15.8%) of endpoint specimens from
Chennai and 9 of 96 patients (9.4%; 95% CI, 4.4%–17.1%) of
endpoint specimens from Mumbai.
Table 1. Baseline and Endpoint Characteristics of Survey Participants
Characteristic
Baseline
(n 5 96)a
Baseline
(n 5 81)b
Chennai
Endpoint
(n 5 81)c
Baseline
(n 5 96)d
Mumbai
Baseline
(n 5 72)e
Endpoint
(n 5 72)f
Sex
Male 61 (63.5) 50 (61.72) Same as baseline 60 (62.5) 44 (61.1) Same as baseline
Female 34 (35.5) 31 (38.28) Same as baseline 36 (37.5) 28 (38.9) Same as baseline
Transgender 1 (1.0) None Same as baseline
Age, y, median (IQR) 36 (33–40) 36 (33–40) Same as baseline 37 (32–41) 39 (32–42) Same as baseline
Weight, kg (female),
median (IQR)
45 (39.75–53.5) 45 (39–53) 46 (42–55) 40 (35–44) 40.5 (38.25–44) 45 (40–48.75)
Weight, kg (male),
median (IQR)
54 (47.25–60) 55.5 (48.75–61) 60 (53–67.25) 50 (45–55) 50 (44.25–56.75) 54 (48–60)
CD41 cell count
(cells/lL)
,200 68 (70.8) 56 (69.1) 7 (8.6) 50 (52.1) 32 (44.4) 9 (12.5)
201–350 28 (29.2) 25 (30.9) 27 (33.3) 38 (39.6) 35 (48.6) 30 (41.7)
$351 None None 47 (58.0) 8 (8.3) 5 (6.9) 33 (45.8)
WHO clinical stage
at baseline
Stage 1 60 (62.5) 48 (66.6) NA
Stage 2 4 (4.2) 4 (5.6) NA
Stage 3 58 (60.4) 50 (61.7) NA 17 (17.7) 10 (13.9) NA
Stage 4 37 (39.6) 31 (38.3) NA 15 (15.6) 10 (13.9) NA
Previous ARV
exposure
3 (3.0) 2 (2.5) NA 13 (13.5) 10 (13.9) NA
ART regimen
ZDV13TC1NVP 50 (52.1) 48 (59.3 38 (46.9) 43 (44.8) 35 (48.6) 28 (38.9)
d4T13TC1EFV 15 (15.6) 12 (14.8) 2 (2.5) 19 (19.8) 12 (16.7) 18 (25.0)
d4T13TC1NVP 22 (22.9) 16 (19.8) 38 (46.9) 25 (26.0) 19 (26.4) 15 (20.8)
ZDV13TC1EFV 9 (9.4) 5 (6.2) 3 (3.7) 9 (9.4) 6 (8.3) 11 (15.3)
HIVDR 5 (6.2) 5 (6.7) 8 (9.9) 10 (10.4) 6 (8.3) 9 (12.5)
HIV RNA (copies/mL)
,1000 (viral load
suppression)
NA NA 72 (88.9) NA NA 62 (86.1)
$1000 (virologic
failure)
NA NA 9 (11.1) NA NA 10 (13.8)
Drug adherenceg
,95% NA NA 8 (9.9) NA NA 10 (13.8)
$95% NA NA 72 (88.8) NA NA 62 (86.1)
Missing data NA NA 1
Data are no. (%) of patients, unless otherwise indicated.
Abbreviations: 3TC, lamivudine; ART, antiretroviral therapy; ARV, antiretroviral; d4T, stavudine; EFV, efavirenz; HIV, human immunodeficiency virus type 1;
HIVDR, HIV drug resistance; IQR, interquartile range; NA, not applicable; NVP, nevirapine; WHO, World Health Organization; ZDV, zidovudine.
a Baseline characteristics of the first consecutive eligible 96 patients from Chennai included in the analysis.
b Baseline characteristics of the 81 patients from Chennai on first-line ART after 12-month endpoint.
c Endpoint characteristics of the 81 patients from Chennai on first-line ART after 12-month endpoint.
d Baseline characteristics of the first consecutive eligible 96 patients from Mumbai included in the analysis.
e Baseline characteristics of the 72 patients from Mumbai on first-line ART after 12-month endpoint.
f Endpoint characteristics of the 72 patients from Mumbai on first-line ART after 12-month endpoint.
g ART adherence assessed by 30-d visual analogue scale at 12-mo endpoint.
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Endpoint HIVDR at Chennai
At endpoint, the most commonly detected NRTI mutation was
M184V (6 of 8 patients) and the most commonly detected
nonnucleoside reverse transcriptase inhibitor (NNRTI) mutation
was K103N (6 of 8 patients). Two of 8 patients had $1 TAM
(Supplementary Table 1).
Endpoint HIVDR at Mumbai
At endpoint, the most frequently observed NRTI mutation was
M184V (8 of 9 patients). K103N was observed in 3 of 9 and
G190A/E in 3 of 9 patients; 4 of 9 patients had $1 TAM
(Supplementary Table 1).
Factors Associated With Genotypic Drug Resistance
In multivariate analyses, the presence of baseline HIVDR
was found to be independently associated with HIVDR at the
12-month endpoint in both the Chennai and Mumbai clinics
(OR, 71.0 [95% CI, 6.4–791.8] and OR, 98.2 [95% CI,
5.5–1746.9], respectively), whereas a CD4 count #200 cells/lL
measured at the visit closest to the 12-month endpoint was
found to be associated with HIVDR at 12 months at the
Chennai clinic only (OR, 9.7 [95% CI, 1.03–91.4]) (Supple-
mentary Table 2). In contrast, age, sex, weight at baseline and
endpoint, self-reported adherence, baseline CD4 count, WHO
stage at baseline, ART regimen at endpoint, and regimen sub-
stitutions were not associated with HIVDR at the 12-month
endpoint at either clinic.
DISCUSSION
The availability and widespread use of ART in high-income
countries has significantly reduced AIDS-related morbidity and
mortality. Rapid ART scale-up in resource-limited settings
(RLSs) has achieved the same benefit. However, concern re-
mains regarding the emergence of significant population-level
HIVDR, which could threaten treatment outcomes. Impor-
tantly, the lack of routine individual VL and HIVDR testing
need not limit optimization of patient care in RLSs. An im-
portant public health strategy includes population-level sur-
veillance of acquired HIVDR and associated ART program
factors. As part of its national HIVDR prevention and assess-
ment strategy, India has implemented WHO global guidelines
for the assessment of acquired HIVDR.
In this survey, the WHO method of assessing acquired
HIVDR was implemented at 2 ART clinics in India. The WHO
target for HIVDR prevention at the population level, defined
by VL suppression 12 months after initiation of ART, is$70%
[12]. Although the proportion of patients with VL suppression
observed in this survey (75% for Chennai and 64.6% for
Mumbai) was lower than that observed in studies from other
countries where different methodologies were used [15–20],
the 75% suppression rate estimated for Chennai does exceed
the WHO suggested target of$70% VL suppression 12 months
after ART initiation. However, the 64.6% VL suppression rate
estimated for the Mumbai clinic fell short of the WHO target
because of the high rate of loss to follow-up (25%) [12]. No-
tably, the VL suppression rate among those on ART at
12 months for the Chennai and Mumbai clinics was 88.8%
(72 of 81) and 86% (62 of 72), respectively, which is com-
parable to cohorts described in other countries [15–22].
Reasons for high rates of loss to follow-up at the Mumbai
clinic include a substantial proportion of patients who are
migrants with no permanent address and inadequate human
resources available for patient tracing. Additionally, some pa-
tients classified as lost to follow-up at both clinics may in fact
have died or transferred care to another facility without
transfer of records. The low proportion of individuals with
detected HIVDR 12 months after ART initiation is compa-
rable to documented prevalence estimates in other RLSs
[17, 22]. Although the proportion of patients failing first-line
ART with HIVDR at 12 months was low, in a country as large
as India with 393 632 individuals receiving ART, a substantial
number of patients failing first-line ART may have HIVDR.
Surprisingly, of 5 patients from the Chennai clinic who had
detected HIVDR at baseline, 1 had VL suppression at the
12-month endpoint. Only 2 of 5 patients (20%) with baseline
HIVDR had self-reported previous ARV exposures. In-
terestingly, at the Mumbai clinic, of 10 patients with HIVDR at
baseline, 2 with baseline NNRTI resistance had suppressed VL at
12 months and 4 were lost to follow-up. Moreover, only 3 of 10
patients with resistance mutations at baseline at the Mumbai
clinic reported previous ARV exposure. This baseline HIVDR
could represent transmitted HIVDR or it may be that patients
had not accurately reported previous ARV exposures during
their interview.
The mutation patterns observed in this survey (Supplementary
Table 1) are consistent with findings published in other studies
from India and other regions [6–8, 10, 11, 23, 24]. The overall
low number of patients with $1 TAM at endpoint suggests
that currently available second-line ART in India (tenofovir/
zidovudine 1 lamivudine 1 lopinavir/ritonavir) is likely to be
effective in the majority of patients failing with HIVDR at
12 months and supports the need for routine VL monitoring
to identify early virological failure. The overall success in
achieving VL suppression in this survey may be attributable to
several factors including the provision of free ART to all
eligible patients [25], standard ART prescribing following
national guidelines, overall high levels of adherence, and low
levels of baseline HIVDR.
This survey does have limitations. Its short duration and
small sample size preclude long-term assessment of first-line
regimen efficacy. Additionally, because only 1 VL test was
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performed at 12 months, the duration of virological failure
could not be estimated and selection of HIVDR could not be
observed. This is important because the time point at which
HIVDR genotyping was performed may have affected the
detected level of resistance or mutation pattern, which is
known to increase in complexity over time in patients
maintained on failing regimens [26]. Additionally, adherence
was assessed by 30-day VAS, which may have been subject to
reporting bias and not on-time pill pickup or medication
possession ratio, which may have provided a more accurate
population-level estimate of pill-taking behavior [27]. Fi-
nally, some participants classified as lost to follow-up may
have in fact died or transferred to another ART clinic without
a transfer of records. Misclassification of deaths or transfers
out as lost to follow-up likely played an important role in our
findings and warrants attention.
As ART is scaled up in India, standardized programmatic
assessment of program factors such as rates of loss to follow-up
at all ART clinics will become increasingly important. Oper-
ational research to define reasons for loss to follow-up, the
development of targeted interventions to minimize loss to
follow-up, and support defaulter-tracing mechanisms are
needed. Specifically, ART clinics such as J. J. Hospital in
Mumbai may benefit from additional human resources to
support patient adherence and defaulter tracing. However, it
should be acknowledged that the ART clinics assessed in this
survey are located in large urban hospitals with strong health
delivery systems; therefore, findings cannot be generalized
to other ART clinics in India.
Results demonstrate the successful implementation of aWHO
survey of acquired HIVDR in India and further strengthen
the consistent observation [15, 16, 19] that high levels of VL
suppression can be achieved in RLSs. Additionally, the survey
highlights the need for routine VL testing to identify viro-
logical failure in individuals receiving first-line ART prior to
selection of multiple TAMs, as concluded in recent reviews
[23, 28]. Finally, findings underscore the need for affordable
second-line ART and mechanisms to minimize loss to follow-up
among patients receiving ART in India’s national program.
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